SCHEMBL5701682

SCHEMBL5701682

CCc1cc(N)c(OC)nc1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.40
NOS3 P29474 2/20 0.35
NOS2 P35228 2/20 0.35
NOS1 P29475 1/20 0.35
P2RX3 P56373 1/20 0.35
P2RX2 Q9UBL9 1/20 0.35
DHFR P00374 1/20 0.35
TAAR1 Q96RJ0 2/20 0.34
MAPT P10636 1/20 0.34
CASP1 P29466 1/20 0.34
AURKA O14965 1/20 0.33
TTK P33981 1/20 0.33
AURKB Q96GD4 1/20 0.33
INCENP Q9NQS7 1/20 0.33
GAA P10253 1/20 0.33
POLB P06746 1/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
GRM1 Q13255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22595837 0.81 POLB (0.35) NOS3NOS2NOS1DHFRGAA
SCHEMBL9432009 0.80 CD274 (0.38) TAAR1GAAPOLBAPOBEC3AAPOBEC3G
SCHEMBL11993969 0.78 PIK3CA (0.41) PIK3CAMAPTCASP1AURKATTK
SCHEMBL9846287 0.78 GAA (0.33) TAAR1GAAPOLBAPOBEC3AAPOBEC3G
SCHEMBL9432036 0.78 GAA (0.36) AURKBGAAPOLBAPOBEC3AAPOBEC3G
SCHEMBL9432058 0.77 TAAR1 (0.50) TAAR1
SCHEMBL9272505 0.76 PDE4A (0.40) MAPTGAAPOLBGRM1
SCHEMBL215544 0.76 PIK3CA (0.41) PIK3CANOS3NOS2NOS1DHFR
SCHEMBL38665916 0.76 PIK3CA (0.41) PIK3CANOS3NOS2NOS1DHFR
SCHEMBL9267418 0.75 ALDH1A1 (0.39) GAAAPOBEC3AAPOBEC3GGRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1073637-B1 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES CENTRE NAT RECH SCIENT (FR) 2006-08-02 EP disclosed
US-6683079-B2 REVERSE TRANSCRIPTASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2004-01-27 US disclosed
US-20030125340-A1 Reverse transcriptase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENT. (FR) 2003-07-03 US disclosed
US-6451822-B1 3-(Amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2002-09-17 US disclosed
EP-1073637-A1 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2001-02-07 EP disclosed
WO-1999055676-A1 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1999-11-04 WO disclosed
US-5780472-A ANTITUMOR AGENTS SAMJIN PHARMACEUTICAZL CO., LTD. (KR) 1998-07-14 US disclosed
EP-0749425-A1 NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME SAMJIN PHARM. CO., LTD. (KR) 1996-12-27 EP disclosed
WO-1996021648-A1 NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME SAMJIN PHARMACEUTICAL CO., LTD. (KR) 1996-07-18 WO disclosed
US-5308854-A 2-benzoxazolylalkyl substituted pyridin-2(1H)(thi)ones; AIDS MERCK & CO., INC. (US) 1994-05-03 US disclosed
EP-0462808-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP disclosed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125340-A1 Reverse transcriptase inhibitors QTRT1, RTF2, POLR1A PIK3CA 2707/4885NOS3 2422/4885NOS2 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.